ATS Life Sciences Systems (LSS) and Stäubli Robotics have joined forces in an exciting new collaboration to develop a state-of-the-art syringe assembly system. Combining the expertise and advanced technologies of both companies, this multi-million-dollar project aims to deliver a highly efficient and reliable end-to-end manufacturing solution.
The partnership between ATS LSS and Stäubli Robotics represents a significant milestone in the automation industry, marking a new era in the production of medical devices. By leveraging Stäubli Robotics’ cutting-edge automation capabilities and integrating them into ATS LSS’ high-performance assembly platform, the companies are poised to meet the unique demands of customers seeking a 300 parts-per-minute syringe assembly system.
This groundbreaking collaboration will utilize eight Stäubli robots across various operations, such as mold unloading, siliconization, tip capping, and comprehensive quality and visual inspections. By combining robotics and automation, the syringe manufacturing system will deliver unparalleled speed, precision, and reliability, ensuring consistent quality and performance.
Olivier Cremoux, the North American Sales and Marketing leader for Stäubli Pharma and Med Devices, expresses his excitement about this partnership: “Stäubli and ATS LSS have established a strategic alliance to develop high-end automation projects for the pharma and medical industry. This collaboration represents a new milestone in our ongoing efforts to provide state-of-the-art automated solutions.”
Andy Glaser, VP of Global Sales at ATS Life Sciences Systems, highlights the unique strengths brought by both companies: “By harnessing the expertise of industry leaders like Stäubli and pairing them with ATS LSS’ innovative solutions, we can tackle even the most complex customer challenges. Together, we are driving transformative solutions that meet the growing market demand for medical devices.”
This groundbreaking collaboration between ATS LSS and Stäubli Robotics is just the beginning. With their combined expertise and commitment to innovation, they are ushering in a new era of automated manufacturing for the life sciences industry. Their collaboration holds great promise for future projects that will redefine production processes, increase efficiency, and contribute to advancements in medical technology.
Frequently Asked Questions
1. What is the goal of the collaboration between ATS LSS and Stäubli Robotics?
The goal of the collaboration is to develop an end-to-end syringe assembly system that is highly efficient, reliable, and capable of producing 300 syringes per minute.
2. How many robots will be employed in the syringe assembly system?
The syringe assembly system will utilize eight Stäubli robots for various operations, including mold unloading, siliconization, tip capping, and quality inspections.
3. What are the benefits of this collaboration?
By combining ATS LSS’ high-performance assembly platform with Stäubli Robotics’ advanced automation capabilities, the collaboration aims to deliver unparalleled speed, precision, and consistency in syringe manufacturing. This will result in improved quality and performance while meeting the unique needs of customers in the medical industry.
4. How does this collaboration contribute to the advancement of medical technology?
The collaboration between ATS LSS and Stäubli Robotics represents a significant step towards revolutionizing the production of medical devices. By incorporating robotics and automation, the syringe assembly system will increase efficiency, improve production processes, and contribute to advancements in medical technology.